Sensorion SA (EPA:ALSEN)

France flag France · Delayed Price · Currency is EUR
0.3640
+0.0240 (7.06%)
Jul 25, 2025, 5:35 PM CET
7.06%
Market Cap109.38M
Revenue (ttm)6.65M
Net Income (ttm)-25.97M
Shares Out300.49M
EPS (ttm)-0.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,276,589
Average Volume499,724
Open0.3220
Previous Close0.3400
Day's Range0.3220 - 0.3730
52-Week Range0.1544 - 0.9700
Beta1.11
RSI57.83
Earnings DateSep 18, 2025

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 63
Stock Exchange Euronext Paris
Ticker Symbol ALSEN
Full Company Profile

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.

Financial Statements

News

Sensorion reports FY results

4 months ago - Seeking Alpha